The molecular mechanisms of sarcomere proteins underlie the contractile function of the
heart. Although our understanding of the sarcomere has grown tremendously, the focus has …

Novel therapies for the treatment of familial dilated cardiomyopathy (DCM) are lacking.
Shaping research directions to clinical needs is critical. Triggers for the progression of the …

In striated muscle, the sarcomeric protein myosin-binding protein-C (MyBP-C) is bound to
the myosin thick filament and is predicted to stabilize myosin heads in a docked position …

The search for small molecules that increase con-tractile function by directly targeting the
muscle of the failing heart can be considered the holy grail in drug development. Thus far …

Myotropes are pharmaceuticals that have recently been developed or are under
investigation for the treatment of heart diseases. Myotropes have had varied success in …

The length-dependent activation (LDA) of maximum force and calcium sensitivity are
established features of cardiac muscle contraction but the dominant underlying mechanisms …

Cardiomyopathies, often caused by mutations in genes encoding muscle proteins, are
traditionally treated by phenotyping hearts and addressing symptoms post irreversible …

Cardiac myosin-binding protein C (cMyBP-C), a sarcomeric protein associated with the thick
filament in the C-zone, finely tunes contractility and relaxation of the heart through its …